{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:24:47Z","timestamp":1762507487315,"version":"3.37.3"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.cjca.2018.08.028","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T16:41:21Z","timestamp":1534783281000},"page":"1426-1436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8493-5123","authenticated-orcid":false,"given":"Jason G.","family":"Andrade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8434-7076","authenticated-orcid":false,"given":"Marc W.","family":"Deyell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Macle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2018.08.028_bib1","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","article-title":"The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms","volume":"114","author":"Andrade","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2018.08.028_bib2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A\u00a0prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2018.08.028_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2018.08.028_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cjca.2017.12.012","article-title":"2018 Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2018.08.028_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM198209163071201","article-title":"A\u00a0controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction","volume":"307","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.08.028_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction: Coumadin Aspirin Reinfarction Study (CARS) Investigators","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.08.028_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ehj.2003.10.026","article-title":"Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study","volume":"25","author":"Herlitz","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.CIR.0000024408.81821.32","article-title":"Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial","volume":"106","author":"Brouwer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.08.028_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.08.028_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial","volume":"360","author":"van Es","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2018.08.028_bib16","article-title":"Antithrombotic therapies for patients with an indication for anticoagulation and stable coronary artery disease: a network meta-analysis [abstract 252]","volume":"34","author":"Yao","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.08.028_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.08.028_bib19","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","article-title":"Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation","volume":"66","author":"Hess","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2018.08.028_bib22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2009.09.001","article-title":"Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST)","volume":"158","author":"Dewilde","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib25","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.08.028_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","article-title":"Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy","volume":"135","author":"Gibson","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.08.028_bib27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2018.08.028_bib28","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/j.cjca.2018.07.192","article-title":"Antithrombotic therapies for patients with an indication for anticoagulation and recent ACS or percutaneous coronary intervention: a network meta-analysis [abstract 221]","volume":"34","author":"Yao","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.08.028_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","article-title":"Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial","volume":"179","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib33","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial","volume":"5","author":"Xu","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.08.028_bib34","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2017.03.011","article-title":"Meta-analysis of the relative efficacy and safety of oral P2Y12 inhibitors in patients with acute coronary syndrome","volume":"119","author":"Shah","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib35","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib36","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.05.085","article-title":"Meta-analyses of dual antiplatelet therapy following drug-eluting stent implantation: do bleeding and stent thrombosis weigh similar on mortality?","volume":"66","author":"Capodanno","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib37","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ehj.2004.03.006","article-title":"Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the \u201cEmperor's New Clothes\u201d revisited","volume":"25","author":"Eriksson","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib38","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib39","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib41","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cjca.2016.07.591","article-title":"2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation","volume":"32","author":"Macle","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib42","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.cjca.2017.06.002","article-title":"Contemporary atrial fibrillation management: a comparison of the current AHA\/ACC\/HRS, CCS, and ESC Guidelines","volume":"33","author":"Andrade","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib43","doi-asserted-by":"crossref","first-page":"e004395","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American Perspective-2016 update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2018.08.028_bib44","doi-asserted-by":"crossref","first-page":"e002524","DOI":"10.1161\/JAHA.115.002524","article-title":"Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy","volume":"4","author":"Costa","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.08.028_bib45","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.08.028_bib46","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.08.028_bib47","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/eurheartj\/ehw683","article-title":"Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors","volume":"38","author":"Pasea","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.08.028_bib48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cjca.2018.08.026","article-title":"for the CCS Atrial Fibrillation Guidelines Committee. 2018 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1831064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X1831064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T21:20:00Z","timestamp":1661808000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X1831064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0828282X1831064X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2018.08.028","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2018.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}